NCT05198804 - A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Ovarian CancerPlatinum-resistant Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer

Interventions

DRUG

ZN-c3

ZN-c3 will be administered.

DRUG

Niraparib

Niraparib will be administered.

Trial Locations (20)

10011

The Blavatnik Family - Chelsea Medical Center at Mount Sinai, New York

22031

Virginia Cancer Specialists, Fairfax

22908

University of Virginia, Charlottesville

23298

Virginia Commonwealth University, Richmond

48201

Karmanos Cancer Institute, Detroit

49503

Spectrum Health System, Grand Rapids

76104

Texas Oncology-Fort Worth Cancer Center, Fort Worth

80012

Rocky Mountain Cancer Centers, Aurora

80045

University of Colorado, Aurora

85711

Arizona Oncology Associates (Wilmot HOPE) - USOR, Tucson

87109

Optimum Clinical Research Group- Women's Oncology, Albuquerque

97401

Willamette Valley Cancer Institute and Research Center, Eugene

07103

Rutgers New Jersey Medical School, Newark

02905

Women and Infants Hospital of Rhode Island, Providence

Unknown

Centre Georges François Leclerc, Dijon

Centre Oscar Lambret, Lille

Centre Hospitalier Lyon Sud, Saint-Genis-Laval

ICANS - Institut de cancérologie Strasbourg Europe, Strasbourg

EDOG - Institut Claudius Regaud, Toulouse

Institut Gustave Roussy, Villejuif

All Listed Sponsors

lead

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

INDUSTRY